Menin Inhibitors Advance Targeted Treatment Strategies in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia
Clinical Summary:
-
Eunice Wang, MD, and Eytan Stein, MD, examine the evolving role of menin inhibitors in acute myeloid leukemia (AML), including genomic testing, measurable residual disease (MRD) assessment, resistance mechanisms, and emerging combination treatment strategies.
-
Menin inhibitors, including revumenib and ziftomenib, have demonstrated clinical activity in molecularly defined AML, while emerging combinations with chemotherapy or azacitidine plus venetoclax may improve response rates and reduce acquired resistance.
-
These developments support increasingly individualized treatment strategies for NPM1-mutated and KMT2A-rearranged AML, with molecular profiling, resistance monitoring, and proactive toxicity management playing important roles as menin inhibitors move into earlier treatment settings.
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, and Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, New York, discuss advances in menin inhibitor therapy for acute myeloid leukemia (AML), including molecularly guided treatment selection, mechanisms of resistance, and emerging combination strategies following their presentations at the Lymphoma, Leukemia & Myeloma Congress in New York, New York.
Dr Wang and Dr Stein review the clinical activity of revumenib and ziftomenib in molecularly defined AML and how emerging combinations with chemotherapy or azacitidine plus venetoclax may improve treatment outcomes. They also discuss the importance of genomic and MRD testing, strategies to overcome acquired resistance, and the management of differentiation syndrome and QT prolongation as menin inhibitors are integrated into AML treatment.
